← boardnext 2027-09-29
ACXP
Acurx Pharmaceuticals Inc.distress 6/10 · elevated risk$1.43-3%today-85% from 52w high
Lead: recurrent C. difficile infection
Revenue
pre-revenue
Liquidity
$9M
Runway
1.5 yrs
Shares 1y
+171%
Price & events
-48.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-10.1%
1W
+0.7%
1M
-28.9%
3M
-48.0%
6M
-84.0%
1Y
-96.9%
2Y
-98.7%
5Y
-99.1%
All
Overview
- Market Cap
- $6.14M
- Volume
- 4.05K
- 52 Week Range
- $1.35 – $9.60
- Total Shares
- 4.30M
- Float Shares
- 4.17M
- Short %
- 3.26%
- % Held by Insiders
- 2.99%
- % Held by Institutions
- 6.17%
- RVOL
- 0.05x
- Beta
- -2.04
Pipeline stages · 1 programs
Ibezapolstat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09-29 Estimated 50% readout ~2027-11-13 | Phase 2 | Ibezapolstat | Clostridium Difficile Infection Recurrence | — | not yet recruiting |
Catalyst news & presentations · 6
- next yearGuided 40%trial initiationsecondaryPhase 3ibezapolstat · Plans to initiate international Phase 3 trials next year, contingent on financing.SEC 8-K
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- July 7-10, 2026Confirmed 100%conferencedata presentationsecondaryibezapolstat · Presentation of experimental data at Anaerobe Society conferenceSEC 8-K
- 2026-04-15partnershipEntered into securities purchase agreement for registered direct offering and private placement.SEC 8-K
- later this monthtrial initiationsecondaryibezapolstat · Start-up activities for open-label pilot trial in multiply-recurrent CDISEC 8-K
- 2025-01-06partnershipRegistered direct offering and private placement of stock and warrants, gross proceeds ~$2.5M.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-09-30HC Wainwright & Co.Buy
- 2025-08-12HC Wainwright & Co.Buy
- 2025-03-19HC Wainwright & Co.Buy
- 2025-01-13HC Wainwright & Co.Buy
- 2025-01-10HC Wainwright & Co.Buy
- 2024-12-10HC Wainwright & Co.Buy
Competitors — recurrent C. difficile infection
- none identified
Recent news
- 2026-07-16Acurx Pharmaceuticals (ACXP) Registration filing Summary - Quartr
- 2026-07-14Acurx data: beneficial gut bacteria remain after repeated C. diff. courses - Stock Titan
- 2026-07-14Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection - Yahoo Finance Singapore
- 2026-07-14Price to earnings forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
- 2026-07-08Acurx to discuss Q2 results and business update Aug. 14 - Stock Titan
- 2026-07-03Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - Ad-hoc-news.de
- 2026-06-25ACXP Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25Acurx Pharmaceuticals (ACXP) Study update presentation Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.